Alkermes (ALKS) EBIT Margin (2010 - 2026)

Alkermes (ALKS) reported EBIT Margin of 122.23% for Q1 2026, down 12673.0% year-over-year from N/an in Q1 2025, and down 908.93% quarter-over-quarter from 15.11% in Q4 2025.

Alkermes (ALKS) EBIT Margin (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has 17 years of EBIT Margin data on file, last reported at 122.23% in Q1 2026.

  • EBIT Margin for Q1 2026 came in at 122.23%, down 12673.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15.87% (down 996.0% YoY), and the FY2025 annual result was 17.21%, down 980.0% from the prior year.
  • EBIT Margin retreated to 122.23% in Q1 2026 per ALKS's latest filing, from 15.11% in the prior quarter.
  • Over five years, EBIT Margin peaked at 45.56% in Q2 2023 and troughed at 1895.03% in Q3 2022.
  • A 5-year average of 171.2% and a median of 15.11% in 2025 frame the typical range for EBIT Margin.
  • The sharpest annual moves came in 2022 and 2023: EBIT Margin slumped 188835 bps in 2022, then jumped 191845 bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 37.94% in 2022, then slumped by 314 bps to 81.28% in 2023, then soared by 147 bps to 37.84% in 2024, then slumped by 60 bps to 15.11% in 2025, then sank by 909 bps to 122.23% in 2026.
  • Business Quant data shows ALKS's EBIT Margin at 122.23% in Q1 2026, 15.11% in Q4 2025, and 22.6% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 16.37%
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 36.83%
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn 41.69%
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn 20.77%
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn 23.74%
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn 22.39%
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn -122.23%
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 21.55%
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn -12.88%
10 Liquidia 5.63 Bn 5.40 Bn 121.79 Mn 46.29%

Historic Data

Download Data
DateValue
Mar 31, 2026 -122.23%
Dec 31, 2025 15.11%
Sep 30, 2025 22.60%
Jun 30, 2025 23.80%
Mar 31, 2025 4.50%
Dec 31, 2024 37.84%
Sep 30, 2024 27.70%
Jun 30, 2024 27.53%
Mar 31, 2024 12.36%
Dec 31, 2023 -81.28%
Sep 30, 2023 23.41%
Jun 30, 2023 45.56%
Mar 31, 2023 -3.82%
Dec 31, 2022 37.94%
Sep 30, 2022 -1,895.03%
Jun 30, 2022 -1,076.78%
Mar 31, 2022 -9.54%
Dec 31, 2021 39.89%
Sep 30, 2021 -6.68%
Jun 30, 2021 1.46%